Compare WHR & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WHR | KOD |
|---|---|---|
| Founded | 1911 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.3B |
| IPO Year | 1994 | 2018 |
| Metric | WHR | KOD |
|---|---|---|
| Price | $40.26 | $39.66 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $74.33 | $35.43 |
| AVG Volume (30 Days) | ★ 2.3M | 541.5K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | ★ 6.59% | N/A |
| EPS Growth | ★ 196.42 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $21,253,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.58 | N/A |
| 52 Week Low | $35.45 | $8.29 |
| 52 Week High | $96.46 | $47.84 |
| Indicator | WHR | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 47.39 | 47.05 |
| Support Level | $38.51 | $38.72 |
| Resistance Level | $45.74 | $46.29 |
| Average True Range (ATR) | 2.00 | 2.79 |
| MACD | -0.29 | -0.48 |
| Stochastic Oscillator | 14.83 | 37.45 |
Whirlpool Corp is a manufacturer and marketer of kitchen and laundry appliances, with its presence in different markets around the world. It offers products like refrigerators, washing machines, cooktops, ovens, freezers, and others, which are marketed through various brands such as KitchenAid, Maytag, Amana, Brastemp, Consul, Whirlpool, Jennair, etc. The company's operating and reportable segments are: Major Domestic Appliances (MDA) North America (its key revenue-generating segment), MDA Europe, MDA Latin America, and Small Domestic Appliances (SDA) Global.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.